Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Thoracic 5Sarcoma 4Lymphoid 3Tumor-Agnostic 2Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Neoplasm Metastasis 1Brain Neoplasms 1

Interventions

Temozolomide 102Radiotherapy 47Bevacizumab 33Carboplatin 23Irinotecan 20pembrolizumab 17Radiosurgery 16Nivolumab 16Radiation 14Cyclophosphamide 11Magnetic Resonance Spectroscopy 10fludarabine 8Trastuzumab 8Radiotherapy, Intensity-Modulated 8Carmustine 8Surgical Procedures, Operative 7Specimen Handling 7Pemetrexed 7Paclitaxel 7Interleukin-2 7Filgrastim 7Everolimus 7Erlotinib Hydrochloride 7temsirolimus 6Vorinostat 6Radiotherapy, Conformal 6Lomustine 6Ipilimumab 6Granulocyte-Macrophage Colony-Stimulating Factor 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Vinorelbine × CNS × Clear all
NCT00026494 2016-01-18

Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
49 enrolled 9 charts
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡